|
I just know Exemestane/Aromasin inhibits Aromatase differently than the non-steroidal inhibitors. I wasn't aware of the secondary cancer issues with Arimidex. I guess you have to look at the numbers. If the chance is very low to begin with, a doubling sounds bad but still may be outweighed by much larger possible benefit regarding the primary cancer. If I were you, I would investigate continuation of Herceptin until more agents that are thought to address cancer stem cells (CSCs)are up to speed. Some feel CSCs are ER-, Her2 + regardless of the makeup of their offspring. In an interview with Dr. Wicha, a CSC researcher, as well as a recent study from St. Gallen, a combination HER2/Endocrine blockade might be a prudent choice until a more definitive framework evolves. Have you had the serum her2 test?
|